15,687 Shares in Quest Diagnostics Incorporated $DGX Acquired by Community Financial Services Group LLC

Key Points

• Community Financial Services Group LLC acquired 15,687 Quest Diagnostics shares worth approximately $3.625 million during the third quarter. Institutional investors collectively own 88.06% of the company.
• Quest Diagnostics reported quarterly EPS of $3.12, beating estimates of $2.82, while revenue rose 10.2% year over year to $3.04 billion. The company’s fiscal 2026 EPS guidance is $11.05–$11.25.
• The company declared a quarterly dividend of $0.86 per share, equivalent to a 1.4% annualized yield. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $237.85, while insiders sold $8.3 million of stock over the past three months.

Community Financial Services Group LLC bought a new stake in shares of Quest Diagnostics Incorporated (NYSE:DGX - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 15,687 shares of the medical research company's stock, valued at approximately $3,625,000.

Other institutional investors have also added to or reduced their stakes in the company. Concurrent Investment Advisors LLC increased its position in shares of Quest Diagnostics by 1.2% during the second quarter. Concurrent Investment Advisors LLC now owns 5,183 shares of the medical research company's stock valued at $1,099,000 after buying an additional 62 shares during the period. PFG Private Wealth Management LLC lifted its holdings in shares of Quest Diagnostics by 5.1% in the second quarter. PFG Private Wealth Management LLC now owns 1,453 shares of the medical research company's stock worth $308,000 after buying an additional 71 shares in the last quarter. Koshinski Asset Management Inc. boosted its position in shares of Quest Diagnostics by 4.2% in the first quarter. Koshinski Asset Management Inc. now owns 2,062 shares of the medical research company's stock valued at $404,000 after acquiring an additional 84 shares during the period. Wedmont Private Capital boosted its position in shares of Quest Diagnostics by 2.8% in the second quarter. Wedmont Private Capital now owns 3,120 shares of the medical research company's stock valued at $647,000 after acquiring an additional 86 shares during the period. Finally, First American Bank boosted its position in shares of Quest Diagnostics by 2.6% in the first quarter. First American Bank now owns 3,472 shares of the medical research company's stock valued at $680,000 after acquiring an additional 89 shares during the period. Hedge funds and other institutional investors own 88.06% of the company's stock.

Quest Diagnostics Stock Up 2.4%

Shares of DGX opened at $238.92 on Friday. The firm has a market cap of $26.37 billion, a P/E ratio of 21.94, a P/E/G ratio of 2.11 and a beta of 0.54. Quest Diagnostics Incorporated has a 1 year low of $171.18 and a 1 year high of $248.84. The stock has a 50 day simple moving average of $237.46 and a two-hundred day simple moving average of $215.21. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.59 and a quick ratio of 1.46.

Quest Diagnostics (NYSE:DGX - Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 earnings per share for the quarter, topping analysts' consensus estimates of $2.82 by $0.30. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The firm had revenue of $3.04 billion during the quarter, compared to analyst estimates of $2.97 billion. During the same period in the previous year, the business posted $2.62 EPS. The business's quarterly revenue was up 10.2% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. On average, analysts forecast that Quest Diagnostics Incorporated will post 11.15 earnings per share for the current fiscal year.

Quest Diagnostics Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 21st. Investors of record on Tuesday, October 6th will be given a $0.86 dividend. This represents a $3.44 dividend on an annualized basis and a yield of 1.4%. The ex-dividend date is Tuesday, October 6th. Quest Diagnostics's dividend payout ratio (DPR) is presently 36.52%.

Insiders Place Their Bets

In other news, SVP Mark E. Delaney sold 1,600 shares of the firm's stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $235.18, for a total transaction of $376,288.00. Following the transaction, the senior vice president directly owned 10,335 shares of the company's stock, valued at approximately $2,430,585.30. This trade represents a 13.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Michael E. Prevoznik sold 22,677 shares of Quest Diagnostics stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $243.11, for a total value of $5,513,005.47. Following the completion of the transaction, the senior vice president owned 37,557 shares in the company, valued at approximately $9,130,482.27. This represents a 37.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 34,277 shares of company stock valued at $8,316,493 over the last three months. Insiders own 0.88% of the company's stock.

Wall Street Analyst Weigh In

DGX has been the topic of several recent analyst reports. Jefferies Financial Group reiterated a "buy" rating and issued a $245.00 target price on shares of Quest Diagnostics in a research note on Thursday, July 23rd. JPMorgan Chase & Co. boosted their price target on shares of Quest Diagnostics from $220.00 to $250.00 and gave the company a "neutral" rating in a research report on Tuesday, July 28th. UBS Group upped their price target on shares of Quest Diagnostics from $232.00 to $245.00 and gave the stock a "neutral" rating in a report on Tuesday, September 8th. Truist Financial upped their price target on shares of Quest Diagnostics from $250.00 to $260.00 and gave the stock a "hold" rating in a report on Monday, September 21st. Finally, Barclays increased their price objective on Quest Diagnostics from $250.00 to $260.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $237.85.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated NYSE: DGX is a provider of diagnostic information services. The company performs laboratory testing that helps physicians, hospitals, health plans, employers and other organizations diagnose, monitor and manage medical conditions.

Its services include routine blood and other clinical laboratory tests, advanced and molecular diagnostics, anatomic pathology, genetic and genomic testing, and testing related to infectious diseases. Quest also provides employer health screening, drug testing, clinical trial support and laboratory information services.

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.